Perioperative outcome and long-term mortality for heart failure patients undergoing intermediate- and high-risk noncardiac surgery: impact of left ventricular ejection fraction

Congest Heart Fail. 2010 Mar-Apr;16(2):45-9. doi: 10.1111/j.1751-7133.2009.00130.x.

Abstract

The impact of left ventricular ejection fraction (LVEF) on outcome in patients with heart failure (HF) undergoing noncardiac surgery has not been extensively evaluated. In this study, 174 patients (mean age, 75+/-12 years, 47% male, mean LVEF (47%+/-18%) underwent intermediate- or high-risk noncardiac surgery. Patients were stratified by LVEF, and adverse perioperative complications were identified and compared. Adverse perioperative events occurred in 53 patients (30.5%), including 14 (8.1%) deaths within 30 days, 26 (14.9%) myocardial infarctions, and 44 (25.3%) HF exacerbations. Among the factors associated with adverse perioperative outcomes in the first 30 days were advanced age (>80 years), diabetes, and a severely decreased LVEF (<30%). Long-term mortality was high, and Cox proportional hazards analysis demonstrated that LVEF was an independent risk factor for long-term mortality.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Adrenergic beta-Antagonists / therapeutic use
  • Aged
  • Aged, 80 and over
  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use
  • Confidence Intervals
  • Female
  • Health Status Indicators
  • Heart Failure / complications
  • Heart Failure / mortality*
  • Heart Failure / physiopathology
  • Humans
  • Kaplan-Meier Estimate
  • Male
  • Myocardial Ischemia / complications
  • Myocardial Ischemia / mortality
  • Myocardial Ischemia / physiopathology
  • Odds Ratio
  • Perioperative Care / adverse effects*
  • Postoperative Complications* / mortality
  • Postoperative Complications* / physiopathology
  • Proportional Hazards Models
  • Retrospective Studies
  • Risk Assessment
  • Risk Factors
  • Stroke Volume*
  • Surgical Procedures, Operative*
  • Time Factors
  • United States / epidemiology
  • Ventricular Function, Left*

Substances

  • Adrenergic beta-Antagonists
  • Angiotensin-Converting Enzyme Inhibitors